Mumbai: Alembic Pharmaceuticals Limited announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Toviaz Extended-Release Tablets, 4 mg and 8 mg, of Pfizer.

This ANDA is indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urinary incontinence, urgency, and frequency.

According to IQVIA, the market for Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, is worth US$ 177 million in the fiscal year ending September 2022.

Alembic had previously received tentative approval for this ANDA.

USFDA gives final approval for this Insomnia drug

USFDA approves this monoclonal antibody to treat multiple sclerosis

USFDA gives final approval to this breast cancer injection

USFDA gives approval for Fulvestrant injection

USFDA gives approval for this Genetic Disorder drug

USFDA gives approval for Lymphoma Therapy

Medical Device alert: CDSCO issues medical device alert on MitraClip Clip Delivery System

Drug recall: Vancomycin Hydrochloride Injection recalled due to this reason

NPPA is in the process of fixing ceiling prices of 63 formulations

Indian scientists discover new Anti-Cancer Agent

Anti-dumping investigation begins on import of Vitamin-A Palmitate

CDSCO panel gives nod for BE study of Tadalafil Oral Jelly

List of approved New Drugs Updated

No need to recall, re-label the drug for price revision if…….:NPPA

Registration for sale of Medical Devices: Procedure and conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2023/01/06/usfda-approves-fesoterodine-fumarate-extended-release-tablets/